Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763154 | 0.90 | BTK (0.40) | ADORA2AADORA2BADORA1CREBBPOPRM1 | |
| SCHEMBL4765716 | 0.86 | ADORA2A (0.43) | ADORA2AADORA2BADORA1KDM5BCREBBP | |
| SCHEMBL4769036 | 0.86 | ADORA2B (0.41) | ADORA2AADORA2BADORA1MTORKDM5B | |
| SCHEMBL4791586 | 0.82 | ADORA2B (0.43) | ADORA2AADORA2BADORA1CREBBPADORA3 | |
| SCHEMBL4771591 | 0.81 | ADORA2B (0.45) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL4771400 | 0.79 | ADORA2B (0.42) | ADORA2AADORA2BADORA1MTORPDE9A | |
| SCHEMBL4864147 | 0.79 | HSP90AA1 (0.41) | ADORA2AADORA2BADORA1MTORKDM5B | |
| SCHEMBL4764038 | 0.78 | ADORA2B (0.44) | ADORA2AADORA2BADORA1KDM5BCREBBP | |
| SCHEMBL4765115 | 0.77 | ADORA2A (0.44) | ADORA2AADORA2BADORA1CREBBPBTK | |
| SCHEMBL4763932 | 0.76 | ADORA2B (0.41) | ADORA2AADORA2BADORA1MTORADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.